5.85 on the TWO. This SniperIQ fundamentals page covers Pharmosa Biopharm's valuation, profitability (net margin -557.6%), revenue (NT$67M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT$4.6B
Net Margin-557.6%
Revenue (FY25)NT$67M

Full research coverage

Frequently Asked Questions

What is Pharmosa Biopharm's market cap?

Pharmosa Biopharm (6875) has a market capitalization of approximately NT$4.6B, trading at NT

5.85 on the TWO. Market cap moves with the live share price.

What is Pharmosa Biopharm's P/E ratio?

Pharmosa Biopharm's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Pharmosa Biopharm?

Pharmosa Biopharm runs a net profit margin of -557.6%, a gross margin of -6.7%, and an operating margin of -572.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Pharmosa Biopharm generate?

Pharmosa Biopharm reported revenue of NT$67M for fiscal year 2025, with net income of -NT

84M and earnings per share (EPS) of -2.97. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Pharmosa Biopharm pay a dividend?

Pharmosa Biopharm does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Pharmosa Biopharm financially healthy?

Pharmosa Biopharm carries a debt-to-equity ratio of 0.08x and a current ratio of 18.10x, with a market beta of 0.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Pharmosa Biopharm a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Pharmosa Biopharm (6875) the key facts are: market cap NT$4.6B, revenue NT$67M, 52-week range 33.6-65. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Pharmosa Biopharm's full fundamentals live

Get Pharmosa Biopharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.